- Home
- GTE vs CLLS Comparison
GTE vs CLLS Comparison
Compare GTE & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTE
- CLLS
- Stock Information
- Founded
- GTE 2003
- CLLS 1999
- Country
- GTE Canada
- CLLS France
- Employees
- GTE N/A
- CLLS N/A
- Industry
- GTE Oil & Gas Production
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- GTE Energy
- CLLS Health Care
- Exchange
- GTE Nasdaq
- CLLS Nasdaq
- Market Cap
- GTE 232.6M
- CLLS 240.2M
- IPO Year
- GTE N/A
- CLLS 2007
- Fundamental
- Price
- GTE $6.47
- CLLS $1.71
- Analyst Decision
- GTE Hold
- CLLS Buy
- Analyst Count
- GTE 1
- CLLS 3
- Target Price
- GTE $10.00
- CLLS $7.00
- AVG Volume (30 Days)
- GTE 396.1K
- CLLS 63.0K
- Earning Date
- GTE 11-04-2024
- CLLS 11-04-2024
- Dividend Yield
- GTE N/A
- CLLS N/A
- EPS Growth
- GTE 157.68
- CLLS N/A
- EPS
- GTE 1.43
- CLLS N/A
- Revenue
- GTE $629,503,000.00
- CLLS $36,042,000.00
- Revenue This Year
- GTE $3.70
- CLLS $271.02
- Revenue Next Year
- GTE $23.85
- CLLS $33.48
- P/E Ratio
- GTE $4.63
- CLLS N/A
- Revenue Growth
- GTE N/A
- CLLS 46.96
- 52 Week Low
- GTE $4.72
- CLLS $1.69
- 52 Week High
- GTE $10.40
- CLLS $3.77
- Technical
- Relative Strength Index (RSI)
- GTE 50.90
- CLLS 34.17
- Support Level
- GTE $6.46
- CLLS $1.85
- Resistance Level
- GTE $7.00
- CLLS $2.09
- Average True Range (ATR)
- GTE 0.26
- CLLS 0.09
- MACD
- GTE -0.01
- CLLS -0.03
- Stochastic Oscillator
- GTE 35.44
- CLLS 0.00
About GTE Gran Tierra Energy Inc.
Gran Tierra Energy Inc is an independent energy company. It is engaged in the acquisition, exploration, development, and production of oil and gas properties. The firm produces light crude oil, supplemented with medium crude and natural gas. Gran Tierra holds interests in producing and prospective properties in Colombia and prospective properties in Ecuador. The company derives its revenue from Colombia.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.